Contact
Max Planck Institute of Biochemistry
Exceptional, results-oriented experts in kinase biology
In the continued effort to bring innovative and differentiated drugs to more patients, the ceedd set out to identify top academic institutions across the world with deep biological expertise and capabilities to translate a biological finding into a drug. In October 2010, The Max Planck Institute (MPI) of Biochemistry in Martinsried and the ceedd signed a research collaboration agreement on the development of novel medicines for the treatment of type II diabetes. The research originated from the labratory of Dr. Axel Ullrich. Dr. Ullrich had previously achieved a milestone in the treatment of diabetes back in the 1970s for the development of genetically engineered human insulin. Dr. Ullrich's other discoveries have led to novel cancer therapies like Herceptin® (Trastuzumab) and SUTENT® (Sunitinib).
The option-based, risk sharing agreement, will look to identify and develop novel compounds that can inhibit kinase activity linked to type II diabetes and control it in a targeted manner. MPI will carry out all in vitro and in vivo work to develop novel therapeutics for treating type 2 diabetes. GSK has an exclusive option throughout the three-year term to exclusively license novel compounds and IP resulting from the program and to take on responsibility for the development of such compounds through clinical studies and for worldwide commercialization.
